✨ Your Portfolio is fetched and updated from zerodha.
Nano Pharmaceuticals

Saroja Pharma Industries India Ltd.

SAROJA

Market Cap
₹13 Cr.
P/E
8.20

Saroja Pharma Industries India Ltd.

Key Ratios

Edit Ratio's
Market cap
Market cap
13.00 Cr
PE
PE
8.20
Prom Holding
Prom Holding
73.02 %
ROE (%)
ROE (%)
6.60
ROCE (%)
ROCE (%)
16.76
Div Yield (%)
Div Yield (%)
-
Sales
Sales
70.24 Cr
OPM (%)
OPM (%)
5.42 %
Debt to Equity
Debt to Equity
0.60
Institutions
Institutions
-
Individual < 2 lac
Individual < 2 lac
19.34 %
No. of Shareholders
No. of Shareholders
413
View more
Edit Ratio's

About

Saroja Pharma Industries India Limited is a leading trader, exporter, and supplier of Specialt… Read more
Low
28
52W Range
High
60
  • Saroja Pharma Ind
  • Emmessar Biotech&Nut
  • Shamrock Indl. Co

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statement

New
Edit rows

Forensics

6 Yes

Positive for this company

2 Neutral

Neutral for this company

6 No

Negative for this company

3 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Peer Comparison

FAQs on Saroja Pharma Industries India Ltd. Business

Saroja Pharma Industries India Limited specializes in trading and exporting Specialty Chemicals for pharmaceutical products. Dedicated to delivering cost-effective human and veterinary medicines with superior quality and service.

Saroja Pharma Inds. major competitors are Emmessar Biotech&Nut, Shamrock Indl. Co, Ortin Global, Norris Medicines, StarsourceMultitrade, Beryl Drugs, Link Pharma Chem.
Market Cap of Saroja Pharma Inds. is ₹13 Crs.
While the median market cap of its peers are ₹13 Crs.

Saroja Pharma Inds. seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

View FAQ's On Shareprice

Company Filing

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release
Investor Presentation
Conference Call
Conference Call SummaryCon Call Summary

Discussions & Analysis

Pharmaceuticals
GLP-1: The Drug Redefining Diabetes, Obesity, and Pharma’s Future - Perpetuity
Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC
Generic Opportunity for Indian Pharma Companies - Anish Moonka
Nutraceuticals- Industry Overview - Value Educator
Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar
Pharma Compliance In-Depth - Amit Rajan
Deep Dive into Pharma Sector - Omkara Capital
How The Pharma Industry Works - PPFAS
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material